Loeven strengthens its commitment to life science, now with attorney Jacob Ørndrup as a partner

With a bigger and stronger team of now three partners, Loeven Law Firm (until 1 January 2022 BKH Law) strengthens its commitment to life science as one of the key practice areas and business sectors of the firm. Attorney Jacob Ørndrup joined the group of partners on 1 January 2022 and will be running Loeven’s life science department together with attorney Christian Vinding Thomsen and attorney Louise Bertelsen Forman.

Two plus one equals far more than three when the experienced Jacob Ørndrup – one of the leading Danish legal practitioners within life science – rings in the New Year of 2022 by moving to Loeven’s life science department where Christian Vinding Thomsen and Louise Bertelsen Forman have been onboarding a string of Danish and international clients from the life science sector since the summer of 2021. With Jacob Ørndrup as part of the team, Loeven will to an even higher degree become one of Denmark’s most high-profile law offices in life science.

Jacob Ørndrup has more than 25 years of experience from cases concerning medicinal products, medical devices, biotech products, foods and chemical products, alongside litigation in intellectual property law disputes, including infringement cases and injunction proceedings. Jacob is widely recognised in Denmark and abroad as a leading expert, particularly in the fields of R&D contracts and licence agreements, pharmaceutical law and healthcare law. Jacob Ørndrup moves to Loeven after 23 years at Gorrissen Federspiel.

”By attracting Jacob, we get a very unique person renowned for his vast professional knowledge and experience of life science to the benefit of our clients and our life science team. Jacob is a truly talented and exceptional person, sharing both our professional and personal values. It is common practice for Danish law firms to have at most one partner specialising in life science – but instead of competing with one another, we have chosen to join forces as this enables us to deliver a much stronger team to the clients while we develop ourselves and our professional skills through our interaction. In this case where the professional and personal values are the same, it is beyond doubt that two plus one is going to represent a much higher value than three”, says Christian Vinding Thomsen, a partner of Loeven.

Asked about his decision to start working with Loeven, Jacob Ørndrup says as follows:
”I’ve accepted the offer to become a part of the life science growth journey in Denmark and elsewhere in Scandinavia for which Loeven has set out a clear strategy in partnership with Christian and Louise, both of whom I have known for years. Together with the other employees in the team, we have a unique opportunity to gather our knowledge, experience and competencies in a strong life science powerhouse, where we can draw on each other’s strengths and skills and, through our joint effort, achieve greater progress in relation to a sector that is constantly evolving and changing. Our synergies create energy, and I look forward to interacting and engaging with them to find solutions for the clients.”

Attorney Jacob Ørndrup has been a partner of Gorrissen Federspiel for the past 19 years. He has more than 25 years of experience from cases concerning pharmaceuticals, medical devices, biotech products, foods and chemical products. Among other duties during his career, he has assisted a substantial number of Danish and international pharma, medtech and biotech companies in litigation and arbitration proceedings and in disputes brought before public authorities and administrative tribunals, including in particular the Danish Medicines Agency and the Ethical Committee for the Pharmaceutical Industry in Denmark (ENLI). Jacob is widely recognised in Denmark and abroad as a leading expert, particularly in the fields of R&D contracts and licence agreements, pharmaceutical law and healthcare law. Jacob Ørndrup is also Vice-Chairman of the Board of the Danish Life Science Law Association.

Christian Vinding Thomsen was a partner of Bech-Bruun for seven years before be came to Loeven on 1 July 2021. He is a member of the boards of directors of a number of life science companies, including Scandion Oncology A/S, a company listed on Nasdaq First North in Stockholm whose mission is to combat chemotherapy resistance. Christian also has a long-standing close collaboration with Practio, which offers digital healthcare solutions and has most recently become known as the company behind Denmark’s optional COVID-19 vaccination scheme. Moreover, Christian is a lecturer in marketing compliance with Atrium, the educational department of the Danish Association of the Pharmaceutical Industry (Lif), and Medtech Denmark, where he also serves as deputy chairman of the Ethics Committee (Udredningspanel).

Louise Bertelsen Forman worked, before joining Loeven, as a senior legal specialist with H. Lundbeck A/S’s Corporate Legal department for three and a half years, where she pursued an international role with global responsibility for marketing compliance and contracts in the fields of R&D and digital solutions across national borders. She was also a member of the Ethics and Compliance Committee for the Pharmaceutical Industry. Before Louise started working for H. Lundbeck A/S, she was an attorney with Bech-Bruun’s IP and life science department. Louise is also a member of the Board of Life Science Law DK, an independent association that aims to promote the development of the legal framework for the life science industries in Denmark.

Share on Linkedin